{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:41:29Z","timestamp":1779892889210,"version":"3.53.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.revmed.2018.02.022","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T21:21:21Z","timestamp":1522790481000},"page":"738-745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Les manifestations oculaires de la maladie de Beh\u00e7et"],"prefix":"10.1016","volume":"39","author":[{"given":"A.-C.","family":"Desbois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Terrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2018.02.022_bib0205","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease. International Study Group for Beh\u00e7et's Disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2018.02.022_bib0210","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Beh\u00e7et's Disease (ICBD): a collaborative study of 27\u00a0countries on the sensitivity and specificity of the new criteria","volume":"28","author":"International Team for the Revision of the International Criteria for Beh\u00e7et's Disease (ITR-ICBD)","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0215","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3109\/09273948.2012.723112","article-title":"Epidemiology of Beh\u00e7et disease","volume":"20","author":"Khairallah","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2018.02.022_bib0220","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","article-title":"Current concepts in the etiology and treatment of Beh\u00e7et disease","volume":"50","author":"Evereklioglu","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0225","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4103\/0974-9233.58425","article-title":"Beh\u00e7et's uveitis","volume":"16","author":"Tugal-Tutkun","year":"2009","journal-title":"Middle East Afr J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0230","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ajo.2017.03.029","article-title":"Randomized controlled trial evaluating a standardized strategy for uveitis etiologic diagnosis (ULISSE)","volume":"178","author":"de Parisot","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0235","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","article-title":"Uveitis in Beh\u00e7et disease: an analysis of 880\u00a0patients","volume":"138","author":"Tugal-Tutkun","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0240","first-page":"S39","article-title":"Genetic association of HLA-A*2601\u00a0with ocular Beh\u00e7et's disease in Japanese patients","volume":"28","author":"Kaburaki","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0245","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/08820530500231953","article-title":"Beh\u00e7et's disease","volume":"20","author":"Bonfioli","year":"2005","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0250","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.survophthal.2004.10.004","article-title":"Laser flare-cell photometry: methodology and clinical applications","volume":"50","author":"Ladas","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0255","first-page":"2878","article-title":"Correlations between laser flare measurements and anterior chamber protein concentrations","volume":"33","author":"Shah","year":"1992","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.revmed.2018.02.022_bib0260","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/IIO.0b013e318265d56a","article-title":"Imaging in the diagnosis and management of Beh\u00e7et disease","volume":"52","author":"Tugal-Tutkun","year":"2012","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.revmed.2018.02.022_bib0265","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","article-title":"The long-term mortality and morbidity of Beh\u00e7et syndrome: a 2-decade outcome survey of 387\u00a0patients followed at a dedicated center","volume":"82","author":"Kural-Seyahi","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.revmed.2018.02.022_bib0270","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3109\/09273948.2012.713159","article-title":"Comparison of presenting features and three-year disease course in Turkish patients with Beh\u00e7et uveitis who presented in the early 1990s and the early 2000s","volume":"20","author":"Cingu","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2018.02.022_bib0275","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/acr.20308","article-title":"Azathioprine in severe uveitis of Beh\u00e7et's disease","volume":"62","author":"Saadoun","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.revmed.2018.02.022_bib0280","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/art.22500","article-title":"Epidemiology and clinical course of Beh\u00e7et's disease in the Reggio Emilia area of Northern Italy: a seventeen-year population-based study","volume":"57","author":"Salvarani","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2018.02.022_bib0285","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ophtha.2007.04.056","article-title":"Clinical features of Chinese patients with Beh\u00e7et's disease","volume":"115","author":"Yang","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2018.02.022_bib0290","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ajo.2011.05.032","article-title":"Beh\u00e7et disease: visual prognosis and factors influencing the development of visual loss","volume":"152","author":"Taylor","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0295","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/bjo.70.8.589","article-title":"Treatment and visual prognosis in Beh\u00e7et's disease","volume":"70","author":"Benezra","year":"1986","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0300","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Beh\u00e7et's syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.02.022_bib0305","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2013.02.002","article-title":"Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies","volume":"12","author":"Saadoun","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2018.02.022_bib0310","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","article-title":"Results of interferon-alfa therapy in patients with Beh\u00e7et uveitis","volume":"244","author":"Tugal-Tutkun","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0315","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bjo.2006.101550","article-title":"Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45\u00a0patients","volume":"91","author":"Bodaghi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0320","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","article-title":"Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Beh\u00e7et uveitis","volume":"129","author":"Onal","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0325","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ajo.2008.09.010","article-title":"Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Beh\u00e7et disease","volume":"146","author":"Tabbara","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0330","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et's disease: multicenter study of 124\u00a0patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.revmed.2018.02.022_bib0335","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/ICU.0b013e32834bbe91","article-title":"Ocular Beh\u00e7et disease: current therapeutic approaches","volume":"22","author":"Evereklioglu","year":"2011","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0340","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Beh\u00e7et's disease: analysis of published data on 369\u00a0patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2018.02.022_bib0345","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/rheumatology\/keu266","article-title":"Anti-TNF-\u03b1 therapy in patients with refractory uveitis due to Beh\u00e7et's disease: a 1-year follow-up study of 124\u00a0patients","volume":"53","author":"Calvo-R\u00edo","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.revmed.2018.02.022_bib0350","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3\u00a0trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2018.02.022_bib0355","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.02.022_bib0360","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1001\/jamaophthalmol.2017.0603","article-title":"Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1\u00a0and VISUAL-2\u00a0trials","volume":"135","author":"Sheppard","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0365","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/art.39667","article-title":"Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the french uveitis network","volume":"68","author":"Vallet","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0370","first-page":"S58","article-title":"Adalimumab for treatment of severe Beh\u00e7et's uveitis: a retrospective long-term follow-up study","volume":"32","author":"Interlandi","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0375","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","article-title":"Efficacy and safety profile of anti-interleukin-1\u00a0treatment in Beh\u00e7et's disease: a multicenter retrospective study","volume":"35","author":"Emmi","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0380","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","article-title":"Interleukin (IL)-1\u00a0inhibition with anakinra and canakinumab in Beh\u00e7et's disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.revmed.2018.02.022_bib0385","first-page":"1","article-title":"Use of gevokizumab in patients with Beh\u00e7et's disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study","author":"Tugal-Tutkun","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2018.02.022_bib0390","first-page":"1","article-title":"Tocilizumab for the treatment of Beh\u00e7et uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy","author":"Eser Ozturk","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2018.02.022_bib0395","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.semarthrit.2015.11.012","article-title":"Tocilizumab in severe and refractory Behcet's disease: four cases and literature review","volume":"45","author":"Deroux","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2018.02.022_bib0200","unstructured":"EULAR recommendations for the management of Beh\u00e7et disease. \u2013\u00a0PubMed\u00a0\u2013 NCBI. Available at: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18245110. (Accessed: 6th December 2017)."}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866318300791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866318300791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:40:13Z","timestamp":1759336813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866318300791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0248866318300791"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2018.02.022","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les manifestations oculaires de la maladie de Beh\u00e7et","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2018.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}